Nasus Pharma Announces Closing of Initial Public Offering

Core Viewpoint - Nasus Pharma Ltd. has successfully closed its initial public offering (IPO) of 1,250,000 ordinary shares at a price of $8.00 per share, raising gross proceeds of $10 million, which will be used to advance its intranasal Epinephrine program and for general corporate purposes [1][2]. Group 1: IPO Details - The IPO consisted of 1,250,000 ordinary shares priced at $8.00 each, resulting in gross proceeds of $10 million before expenses [1]. - Shares began trading on the NYSE American LLC under the ticker symbol "NSRX" on August 13, 2025 [1]. - Underwriters have an option to purchase an additional 187,500 shares within 45 days at the IPO price [1]. Group 2: Use of Proceeds - The net proceeds from the IPO will primarily fund the development of the intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies [2]. - Remaining funds will be allocated for general and administrative purposes, including working capital and capital expenditures [2]. Group 3: Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute medical conditions [5]. - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine designed as a needle-free alternative for anaphylaxis treatment [5]. - The proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [5].